Announcement of the Medicines for Europe of which AFAQUIM is affiliate member.
Medicines for Europe, the association representing the pharmaceutical industry of generic, biosimilar and value-added medicines throughout Europe, announced today the appointment of Elisabeth Stampa as the new president of the entity. With over twenty years in the industry, Elisabeth Stampa is currently CEO of Medichem, S.A. and member of its Board of Directors. She has previously served as executive president of the corporate family business (Medichem, S.A. and the former Combino Pharm, S.L.), having started her career at Laboratorios Esteve. She holds a bachelor’s degree in Pharmacy from the University of Barcelona and a Master’s Degree in Business Administration from Esade Business & Law School. In addition, she is a member of the Board of Companies of the Chemical Institute of Sarriá (IQS), a higher education institution based in Barcelona.
Elisabeth Stampa has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen European industry globally. In that sense, she has represented European manufacturers of active ingredients (API) on behalf of the European Fine Chemicals Group (EFCG) in negotiations with the US Food and Drug Administration (FDA). She has also been an active representative of the sector of Fine Chemistry manufacturers, especially Active Pharmaceutical Ingredients (APIs) and their intermediates as a member of the Board of Directors of AFAQUIM until the end of 2021.
COVID-19 pandemic has highlighted the critical relationship between patient access to medicines and a strong drug manufacturing sector. As health systems begin to recover from the pandemic, a new crisis threatens stability and the secure supply of medicines in Europe highlighting the urgency of coordinating European Union (EU) actions on essential medicines and access to care, translating political statements into real reforms. Taking office as President of Medicines for Europe, Elisabeth Stampa has set out the following key policy priorities that require urgent action by the EU.
- 1. Facilitate the sustainable manufacture of active ingredients and medicines in the EU to ensure supply to patients and health systems in Europe.
- 2. Ensure the competitiveness of the European sector of active ingredients and medicines outside patent together with a flexible and digital regulatory system that facilitates timely access for patients.
- 3. Support the green transformation of the manufacture of active ingredients and medicines.
In her remarks at the beginning of her mandate, Elisabeth Stampa has pointed out that “seven out of ten drugs dispensed in Europe are off-patent medicines. Our industry has made a significant contribution during the pandemic and now a major war is starting at our borders. The off-patent medicines sector is a key contribution to the European healthcare system. Medicines for Europe’s interests are fully in line with the EU’s pharmaceutical and industrial objectives. The time has come to fulfill them. My priority as president will be to work with the EU to improve access to medicines and restore the competitiveness of manufacturing in Europe.
- 1. To this end, among other things, we must advocate for the elimination of short-term cost containment policies that aggravate both the risk of drug shortages and dependence on other territories and, ultimately, harm patients.
- 2. I want to ensure that the intellectual property system works as designed for patients in a way that makes it easier for them to access the medicines they need.
- 3. I want our partnership to embrace the green and digital transformation of healthcare while continuing to provide high-quality medicines to patients.
I trust our members, stakeholders and partners will respond to the challenges that lie ahead and we will do everything in our power to offer better access and better health to the entire European population.”
The appointment of Elisabeth Stampa marks the end of the term of Rebecca Guntern (Sandoz), who has led the association on an interim basis for the past six months. Guntern will continue her active engagement with Medicines for Europe in her role as vice president of the association. “It has been an honour to lead Medicines for Europe during this interim period. The off-patent drug industry continues to provide access to as many patients as possible, even in the most difficult circumstances. I wish Elizabeth all the best,” said Rebecca Guntern.